XML 33 R23.htm IDEA: XBRL DOCUMENT v2.4.0.6
Deferred Revenue
12 Months Ended
Dec. 31, 2011
Deferred Revenue [Abstract]  
Deferred Revenue

Note 15. Deferred Revenue

Deferred Revenue related to Licensing Agreement

In August 2006, we entered an agreement with Stem Cell Therapeutics (SCT), a Canadian corporation, granting it a non-exclusive, royalty-bearing license to use several of our patents for treating specified diseases of the central nervous system; the grant does not include any rights to cell transplantation. SCT granted StemCells a royalty-free non-exclusive license to certain of its patents for research and development and a royalty-bearing non-exclusive for certain commercial purposes. SCT paid an up-front license fee; the license also provides for other payments including annual maintenance, milestones, and royalties. The up-front license fee is being amortized and recognized as revenue over a period of 12 years. At December 31, 2011, the unamortized amount of deferred revenue related to this agreement was approximately $140,000.